Navigation Links
FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
Date:5/4/2010

eling is based on a 14-hour modified analog classroom study of Vyvanse to simulate a workplace environment in 142 adults who met DSM-IV-TR criteria for ADHD.  The data support the results of a previous Phase 3 clinical study of adults with ADHD in which Vyvanse significantly improved the ADHD symptoms of inattention (for example, lack of focus), as well as of hyperactivity and impulsivity, as measured by the ADHD Rating Scale (ADHD-RS-IV) with adult prompts, a standard validated tool.  The most common treatment-emergent adverse events in patients taking Vyvanse in this previous study were decreased appetite, trouble sleeping, dry mouth, nausea, diarrhea, anxiety and loss of appetite.

As with other stimulant medications, Vyvanse is classified as a controlled substance (CII) because of its potential for abuse.

About the Study

The data that led to this approval of revised labeling for Vyvanse was from a multi-center, randomized, double-blind, placebo-controlled, crossover study in 142 adults who met DSM-IV-TR criteria for ADHD.  Following a 4-week, open-label, dose-optimization phase with Vyvanse (30, 50, or 70 mg/day in the morning), subjects were randomized to one of two treatment sequences:  Vyvanse (optimized dose) followed by placebo, each for one week, or placebo followed by Vyvanse, each for one week.  Efficacy assessments occurred at the end of each week, using the PERMP.  The PERMP is a skill-adjusted math test that measures attention in ADHD.  Vyvanse treatment, compared to placebo, resulted in a statistically significant improvement in attention across all postdose time poin
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
2. FDA Approves New Device for Adults with Severe and Persistent Asthma
3. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
4. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
5. FDA Approves First Totally Implanted Hearing System
6. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
7. FDA Approves Name Change for Heartburn Drug Kapidex
8. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
9. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
10. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
11. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Nov. 23, 2014  Aurobindo Pharma USA ... Capsules, USP 300 mg 100-count bottles to the consumer ... some empty capsules. Empty capsules could result ... consequences that could range from no effect, short term ... epilepticus (long period seizures) that could be life-threatening. Aurobindo ...
(Date:11/22/2014)... , Nov. 21, 2014   Long Beach dentist , ... often called the gold standard in tooth replacement because they ... stable, long-lasting way to restore and preserve smiles and improve ... replace a missing tooth or as a part of a ... look and feel of a smile. The loss ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... 18 Epiphany Biosciences announced results from its Phase ... shingles (herpes zoster) infection. The study,s primary endpoint ... in terms of time to complete crusting of the ... randomized into 3 arms: 1 gram of once-daily ...
... Nov. 18 Covance Inc. (NYSE: CVD ), ... it entered into a biomarker alliance and services agreement with ... biomarker testing to the pharmaceutical industry. , Subject to the ... exclusive third-party provider of multiplexed protein biomarker testing services, and ...
Cached Medicine Technology:Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 2Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 4
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... Lake City, Utah (PRWEB) November 23, 2014 ... individual health insurance reimbursement for small businesses, announced ... new book, The End of Employer-Provided Health Insurance. ... health insurance is the greatest financial risk facing ... challenge facing U.S. employers, small and large, when ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota ... tunnels and the growth and spread of mesothelioma. ... the Surviving Mesothelioma website. , Doctors at Memorial ... have just released their study on tunneling nanotubes (TnTs), ... They found that mesothelioma cells contain many ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
Breaking Medicine News(10 mins):Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2
... SHENZHEN, China, Sept. 21 /PRNewswire-Asia/ -- ... or the "Company"), a leading,exporter of medical dressing and ... sponsored the "2009 China Medical Textile Industry,Forum -- Innovation ... China. , The organizer of ...
... , , LINCOLN, R.I., Sept. 21 ... Americans report problems with chronic pain; more than diabetes, heart disease, ... of chronic pain in the United States, including healthcare expenses, lost ... , "Despite the obvious impact on our society and ...
... , , BIRMINGHAM, Ala., ... today announced that it has been awarded a $77.2 million contract ... to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous ... , "We are very excited to continue working ...
... , PRINCETON, N.J., Sept. 21 ... Company), a late-stage biotechnology company, announced today that it has ... Institute of Allergy and Infectious Diseases (NIAID), a division of ... over a five-year period, the development of formulation and manufacturing ...
... , , INDIANAPOLIS, Sept. 21 ... in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who ... care as compared to placebo plus best supportive care. ... previous studies looking at the use of histology to tailor treatment ...
... , , , ... today announced U.S. Food & Drug Administration clearance to market ... is the first and only blood glucose monitor that plugs ... information that can help optimize diabetes management. The CONTOUR USB ...
Cached Medicine News:Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 2Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 3Health News:Measuring Pain from the Patient's Point of View 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 3Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 4Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 2Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 3Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 4Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 2Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 3Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 4Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 5Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 7Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 8Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 2Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 3Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 4Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 5
... Pediatric Sarmiento-style PTB tibial orthosis ... Lined with closed-cell foam at bony ... Selection of 3 modular footpiece/shoe insert ... patient. Stretch Velcro® design fits especially ...
... is a lightweight patient friendly brace utilizing the ... The Escort provides patients with a lightweight ... Superior comfort and improved patient compliance is ... Escort Hip brace is the result of ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
Medicine Products: